Piperidine derivatives as serotonine reuptake inhibitors
AssigneeEli Lilly and Company
InventorsSidney Xi Liang, Yao-Chang Xu
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds of formula I and a method of inhibiting the reuptake of serotonin, antagonizing the 5-HT1A receptor and antagonizing the 5-HT2A receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of formula I.
Claims17
A compound of the formula:
- wherein:
- X represents O or S;
- Y represents —C(═O)—, —CH(OH)—, —CH2—, S, SO, or SO2;
- represents a single or a double bond;
- n is 1, 2, 3 or 4;
- R1a, R1b, R1c, and R2 are each independently H, F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, —NR7R8, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R3 represents H, OH, hydroxy(C1-C6)alkyl, C1-C6 alkyl, or C1-C6 alkoxy;
- R4 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R5 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or C3-C8 cycloalkyl substituted with C1-C4 alkyl;
- R6a and R6b are each independently H or C1-C3 alkyl;
- R7 and R8 are each independently H, C1-C6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or a pharmaceutically acceptable salt thereof.
A compound which is 4-(4-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl)butan-1-one or a pharmaceutically acceptable salt thereof.
A compound which is 4-(4-benzo(b)thiophene-1,2,3,6-tetrahydropyridyl)-1-cyclohexyl-2-(2-pyridyl)butan-1-one.
A method of inhibiting the reuptake of serotonin and antagonizing the 5-HT1A receptor which comprises administering to a subject in need of such treatment an effective amount of a compound of the formula:
- wherein:
- X represents O or S;
- Y represents —C(═O)—, —CH(OH)—, —CH2—, S, SO, or SO2;
- represents a single or a double bond;
- n is 1, 2, 3 or 4;
- R1a, R1b, R1c, and R2 are each independently H, F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, —NR7R8, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R3 represents H, OH, hydroxy(C1-C6)alkyl, C1-C6 alkyl, or C1-C6 alkoxy;
- R4 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R5 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C(,)alkyl, phenyl, NO2, NH2, or CN;
- heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl,C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or C3-C8 cycloalkyl substituted with C1-C4 alkyl;
- R6a and R6b are each independently H or C1-C3 alkyl;
- R7 and R8 are each independently H, C1-C6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or a pharmaceutically acceptable salt thereof.
A method of potentiating the action of a serotonin reuptake inhibitor comprising administering to a subject in of such treatment a compound formula:
- wherein:
- X represents O or S;
- Y represents —C(═O)—, —CH(OH)—, —CH2—, S, SO, or SO2;
- represents a single or a double bond;
- n is 1, 2, 3 or 4;
- R1a, R1b, R1c, and R2 are each independently H, F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, —NR7R8, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R3 represents H, OH, hydroxy(C1-C6)alkyl, C1-C6 alkyl, or C1-C6 alkoxy;
- R4 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R5 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl,C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or C3-C8 cycloalkyl substituted with C1-C4 alkyl;
- R6a and R6b are each independently H or C1-C3 alkyl;
- R7 and R8 are each independently H, C1-C6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or a pharmaceutically acceptable salt thereof.
A method of treating depression comprising administering to a subject in need thereof an effective amount of a compound of formula:
- wherein:
- X represents O or S;
- Y represents —C(═O)—, —CH(OH)—, —CH2—, S, SO, or SO2;
- represents a single or a double bond;
- n is 1, 2, 3 or 4;
- R1a, R1b, R1c, and R2 are each independently H, F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, —NR7R8, CN or phenyl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R3 represents H, OH, hydroxy(C1-C6)alkyl, C1-C6 alkyl, or C1-C6 alkoxy;
- R4 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- R5 represents aryl, heterocycle, C3-C8 cycloalkyl, aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- heterocycle substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl,C1-C6 alkoxy, hydroxy(C1-C6)alkyl, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or C3-C8 cycloalkyl substituted with C1-C4 alkyl;
- R6a and R6b are each independently H or C1-C3 alkyl;
- R7 and R8 are each independently H, C1-C6 alkyl, aryl or aryl substituted with from 1 to 3 substituents selected from the group consisting of F, Cl, Br, I, OH, C1-C6 alkyl, C1-C6 alkoxy, halo(C1-C6)alkyl, phenyl, NO2, NH2, or CN;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.